From The Economic Times · Spotlight Wire · · 1m 20s
Lord's Mark AI breast cancer screening nears clinical trials
Lord's Mark's AI-powered radiation-free breast cancer screening technology advances to final clinical trials across global markets.
In brief
Lord's Mark's AI-powered radiation-free breast cancer screening technology advances to final clinical trials across global markets. Lord's Mark Industries Limited's AI breast cancer screening technology will begin phase 2 trials in 2027 targeting 98% accuracy for early detection. Originally reported by The Economic…
AI breast cancer screening technology
Lord's Mark Industries Limited has progressed its AI-powered radiation-free wearable breast cancer screening technology towards final clinical trials.
Global clinical trial plans
Trials will begin in india, the usa, europe, and great britain starting january 2027 for 98% accuracy cell-level cancer detection.
Market context
Breast cancer affects 2.4 million women globally with 694,000 deaths in 2024, driving a $5.9 billion diagnostics market projected to reach $11.4 billion by 2033.
Technology approach
The wearable uses high-precision thermal sensors and ai-based temperature mapping to detect abnormalities without radiation.
Regulatory progress
The technology has completed clinical trials in india and is targeting cdsc approval in india and regulatory pathways in the us and europe by march 2027.
Commercial timeline
Lord's Mark plans to commercialize the product by april 2027 after successful clinical validation and regulatory approvals.
Healthcare access goals
The company seeks integration into national screening programs and insurance frameworks to improve affordability and accessibility globally.
The short version
Lord's Mark Industries Limited's AI breast cancer screening technology will begin phase 2 trials in 2027 targeting 98% accuracy for early detection.
